Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

Rennes University Hospital

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Other: Biomarkers analysis

Study type: Observational

Funder types: Other

Identifiers

NCT04510350

35RC19_8880_CISCO

Details and patient eligibility

About

The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.

Enrollment: 90 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Patients :

Inclusion Criteria:

• Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort (French MS Observatory)
• At least 18 years of age
• Diagnosed with MS according to criteria 2017 at the time of their last visit.
• Non-opposition to participation in the study
• Having had at least one visit in the year following collection
• Follow-up for at least 1 year after collection.
• Having signed the OFSEP consent

Exclusion Criteria:

• CIS patients with progressive MS

Healthy volunteers :

Inclusion Criteria:

• Age 18 years or older
• Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351).
• Matched on age and sex to patients of interest in the OFSEP cohort
• Not having objected to participation in the study

Exclusion Criteria:

• Persons of full age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty

Trial design

90 participants in 2 patient groups

MS CIS+

Treatment:

Other: Biomarkers analysis

Healthy volunteers

Treatment:

Other: Biomarkers analysis